Skip to main content
. Author manuscript; available in PMC: 2021 Jan 14.
Published in final edited form as: Ann Surg Oncol. 2020 May 20;27(11):4475–4485. doi: 10.1245/s10434-020-08608-1

Fig. 3.

Fig. 3

Nottingham Grade 3 BCs demonstrated significantly higher pCR rate in response to NAC in the GSE25066 cohort (p<0.001). Other two cohorts (GSE22226 and GSE22358) also demonstrated trends towards higher pCR rate in Grade 3 tumors (p=0.06 and 0.09, respectively).

BC, Breast cancer; pCR, pathological complete response; NAC, neoadjuvant chemotherapy